-
HELSINN HEALTHCARE S.A. et al v. DR. REDDY'S LABORATORIES, LTD. et al DC CAFC
- 2:11-cv-03962
- D.N.J.
- Judge: Stanley R. Chesler
+1
- Filed: 07/08/2011
- Closed: 11/16/2015
- Latest Docket Entry: 06/11/2018
- PACER
2
Plaintiffs
5
Defendants
2
Accused
Products
2
Patents-in-Suit
1,593
Days in
Litigation
-
HELSINN HEALTHCARE S.A. et al v. DR. REDDY'S LABORATORIES, LTD. et al DC CAFC
- 2:11-cv-03962
- D.N.J.
- Judge: Stanley R. Chesler
+1
- Filed: 07/08/2011
- Closed: 11/16/2015
- Latest Docket Entry: 06/11/2018
- PACER
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 2 |
The solution of claim 1 wherein the palonosetron or pharmaceutically acceptable salt thereof is in concentration of about 0.05 mg/ml.
|
Valid
Entry 360 Entry 361 |
| 9 |
The solution of claim 8 wherein the palonosetron or pharmaceutically acceptable salt thereof is in concentration of about 0.05 mg/ml.
|
Valid
Entry 360 Entry 361 |
| All Claims |
NA
|
Enforceable and Invalid
Entry 247 Entry 401 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 2 |
A pharmaceutically stable solution for reducing emesis or reducing the likelihood of emesis comprising: a) 0.05 mg/mL palonosetron hydrochloride, based on the weight of the free base, in a sterile injectable aqueous carrier at a pH of from 4.5 to
view more
|
Invalid
Entry 401 |
| All Claims |
NA
|
Enforceable and Valid
Entry 247 |
-
Infringement
Teva Pharmaceutical Europe BV
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 0.075 mg generic palonosetron hydrochloride intravenous solutions0.25 mg generic palonosetron hydrochloride intravenous solutionsGeneric 0.25 mg/5 mL and 0.075mg/1.5 mL palonosetron hydrochloride intravenous solutionGeneric palonosetron hydrochloride intravenous solution products (0.25 mg / 5 mL and 0.075 mg / 1.5 mL)Generic version of hydrochloride intravenous solution 0.075 / l .5 mL mg productGeneric version of hydrochloride intravenous solution 0.25 mg / 5 mL product | US 7,947,724 B2 |
2, 9
|
Infringement
Entry 360Entry 361 |
| 0.075 mg generic palonosetron hydrochloride intravenous solutions0.25 mg generic palonosetron hydrochloride intravenous solutionsGeneric 0.25 mg/5 mL and 0.075mg/1.5 mL palonosetron hydrochloride intravenous solutionGeneric palonosetron hydrochloride intravenous solution products (0.25 mg / 5 mL and 0.075 mg / 1.5 mL)Generic version of hydrochloride intravenous solution 0.075 / l .5 mL mg productGeneric version of hydrochloride intravenous solution 0.25 mg / 5 mL product | US 7,947,725 B2 |
2
|
Infringement
Entry 360Entry 361 |
Teva Pharmaceutical Industries Limited
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 0.075 mg generic palonosetron hydrochloride intravenous solutions0.25 mg generic palonosetron hydrochloride intravenous solutionsGeneric 0.25 mg/5 mL and 0.075mg/1.5 mL palonosetron hydrochloride intravenous solutionGeneric palonosetron hydrochloride intravenous solution products (0.25 mg / 5 mL and 0.075 mg / 1.5 mL)Generic version of hydrochloride intravenous solution 0.075 / l .5 mL mg productGeneric version of hydrochloride intravenous solution 0.25 mg / 5 mL product | US 7,947,724 B2 |
2, 9
|
Infringement
Entry 360Entry 361 |
| 0.075 mg generic palonosetron hydrochloride intravenous solutions0.25 mg generic palonosetron hydrochloride intravenous solutionsGeneric 0.25 mg/5 mL and 0.075mg/1.5 mL palonosetron hydrochloride intravenous solutionGeneric palonosetron hydrochloride intravenous solution products (0.25 mg / 5 mL and 0.075 mg / 1.5 mL)Generic version of hydrochloride intravenous solution 0.075 / l .5 mL mg productGeneric version of hydrochloride intravenous solution 0.25 mg / 5 mL product | US 7,947,725 B2 |
2
|
Infringement
Entry 360Entry 361 |